Haleon plc (NYSE:HLN) Given Average Rating of “Hold” by Analysts

Haleon plc (NYSE:HLN) has been assigned an average rating of “Hold” from the eight research firms that are currently covering the firm, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have covered the stock in the last year is $10.95.

A number of research analysts have recently issued reports on HLN shares. HSBC restated a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Sanford C. Bernstein downgraded Haleon from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of Haleon in a research note on Monday, March 3rd. Hsbc Global Res cut Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. Finally, Morgan Stanley cut shares of Haleon from an “overweight” rating to an “equal weight” rating in a report on Friday, January 10th.

Haleon Stock Up 0.6 %

Shares of NYSE:HLN opened at $10.22 on Monday. The business has a fifty day simple moving average of $10.09 and a 200 day simple moving average of $9.80. Haleon has a 12-month low of $8.12 and a 12-month high of $10.80. The firm has a market cap of $46.16 billion, a P/E ratio of 30.06, a P/E/G ratio of 2.82 and a beta of 0.24. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last issued its quarterly earnings data on Thursday, February 27th. The company reported $0.05 earnings per share (EPS) for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The company had revenue of $3.54 billion during the quarter, compared to the consensus estimate of $3.38 billion. Analysts predict that Haleon will post 0.43 earnings per share for the current year.

Haleon Increases Dividend

The firm also recently declared a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be given a $0.1166 dividend. The ex-dividend date is Friday, April 25th. This represents a yield of 1.6%. This is an increase from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is presently 58.97%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of HLN. Jane Street Group LLC raised its holdings in shares of Haleon by 1,689.4% in the 3rd quarter. Jane Street Group LLC now owns 264,977 shares of the company’s stock worth $2,803,000 after acquiring an additional 250,169 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Haleon in the third quarter valued at approximately $203,000. Synovus Financial Corp grew its holdings in Haleon by 0.8% during the third quarter. Synovus Financial Corp now owns 148,834 shares of the company’s stock worth $1,575,000 after buying an additional 1,216 shares in the last quarter. Peapack Gladstone Financial Corp grew its holdings in Haleon by 3.2% during the third quarter. Peapack Gladstone Financial Corp now owns 44,844 shares of the company’s stock worth $474,000 after buying an additional 1,390 shares in the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Haleon by 25.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 5,084,202 shares of the company’s stock valued at $53,791,000 after acquiring an additional 1,026,939 shares in the last quarter. Institutional investors and hedge funds own 6.67% of the company’s stock.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.